Jagsonpal Pharmaceuticals Announces 47th AGM on September 18, 2026
Jagsonpal Pharmaceuticals will hold its 47th AGM on September 18, 2026, via Video Conference. A final dividend of ₹4 per share is recommended, with a record date of September 4, 2026. The dividend will be paid within 30 days of AGM approval.
The announcement is about the scheduling of the AGM and a standard dividend declaration, which are routine corporate events and do not significantly impact the company's current operations or financial standing.
The announcement is a routine corporate communication regarding the AGM and dividend declaration. It does not contain any significant positive or negative financial news.
Jagsonpal Pharmaceuticals Limited has announced that its 47th Annual General Meeting (AGM) will be held on Friday, September 18, 2026, at 3:30 PM IST. The meeting will be conducted entirely through Video Conferencing (VC) / Other Audio Visual Means (OAVM), provided by National Securities Depository Limited (NSDL).
In compliance with regulations and circulars from the Ministry of Corporate Affairs (MCA) and SEBI, the Notice of the AGM along with the Annual Report for the financial year 2025-26 will be sent electronically to members whose email addresses are registered. These documents will also be available on the company's website (www.jagsonpal.com) and the websites of BSE and NSE.
The Board of Directors, in their meeting held on April 27, 2026, recommended a final dividend of ₹4 per equity share (200%) for the financial year 2025-26. The record date for this dividend is September 4, 2026. The dividend, once approved at the AGM, will be paid within 30 days. Shareholders are reminded that dividend income is taxable and the company will deduct tax at source (TDS) at the prescribed rates. Tax exemption documents and other relevant information should be submitted by September 4, 2026.
Mr. Ayush Khandelwal has been appointed as the Scrutinizer to oversee the remote e-voting and the voting process during the AGM.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.